- Home
- MIRM vs MGIC Comparison
MIRM vs MGIC Comparison
Compare MIRM & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MGIC
- Stock Information
- Founded
- MIRM 2018
- MGIC 1983
- Country
- MIRM United States
- MGIC Israel
- Employees
- MIRM N/A
- MGIC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MGIC Computer Software: Prepackaged Software
- Sector
- MIRM Health Care
- MGIC Technology
- Exchange
- MIRM Nasdaq
- MGIC Nasdaq
- Market Cap
- MIRM 1.9B
- MGIC N/A
- IPO Year
- MIRM 2019
- MGIC 1991
- Fundamental
- Price
- MIRM $40.00
- MGIC $13.67
- Analyst Decision
- MIRM Strong Buy
- MGIC Buy
- Analyst Count
- MIRM 11
- MGIC 2
- Target Price
- MIRM $58.55
- MGIC $16.00
- AVG Volume (30 Days)
- MIRM 447.2K
- MGIC 53.4K
- Earning Date
- MIRM 05-07-2025
- MGIC 05-15-2025
- Dividend Yield
- MIRM N/A
- MGIC 4.10%
- EPS Growth
- MIRM N/A
- MGIC N/A
- EPS
- MIRM N/A
- MGIC 0.75
- Revenue
- MIRM $336,888,000.00
- MGIC $552,520,000.00
- Revenue This Year
- MIRM $29.51
- MGIC $7.53
- Revenue Next Year
- MIRM $20.27
- MGIC $4.89
- P/E Ratio
- MIRM N/A
- MGIC $18.29
- Revenue Growth
- MIRM 80.76
- MGIC N/A
- 52 Week Low
- MIRM $23.14
- MGIC $9.51
- 52 Week High
- MIRM $54.23
- MGIC $14.24
- Technical
- Relative Strength Index (RSI)
- MIRM 41.05
- MGIC 58.16
- Support Level
- MIRM $38.22
- MGIC $13.03
- Resistance Level
- MIRM $40.14
- MGIC $13.99
- Average True Range (ATR)
- MIRM 2.24
- MGIC 0.40
- MACD
- MIRM 0.07
- MGIC 0.06
- Stochastic Oscillator
- MIRM 48.50
- MGIC 84.08
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.